Incyte (INCY) EBITDA Margin (2010 - 2026)
Incyte's EBITDA Margin was 43.27% in Q2 2026, down 2.24 percentage points from 45.51% a year earlier but up 17.74 percentage points from the prior quarter.
Powered by 
Analysis
Incyte (INCY) EBITDA Margin (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Incyte's EBITDA Margin was 32.25% through Jun 30, 2026, up 4.47 percentage points year-over-year; for FY2025, it came in at 31.28%, up 27.73 percentage points from FY2024.
- EBITDA Margin shows a five-year change of +39.22 percentage points (FY2020 to FY2025).
- In earlier years, EBITDA Margin was 3.55% in FY2024 (-15.48 pp), 19.03% in FY2023 (-0.04 pp), 19.07% in FY2022 (-2.48 pp) and 21.55% in FY2021 (+29.50 pp).
- Quarterly EBITDA Margin has moved between -43.70% (Q2 2024) and 45.51% (Q2 2025) over five years.
- Compared with a year earlier, EBITDA Margin was higher in five of the last eight quarters, with an average year-over-year change of +13.92 percentage points.
- The best year-over-year quarter for EBITDA Margin over five years was Q2 2025 (a gain of 89.21 percentage points); the worst was Q2 2024 (a drop of 66.12 percentage points).
- Per Business Quant data, INCY's EBITDA Margin in the three quarters before Q2 2026 was 25.53% (Q1 2026), 23.88% (Q4 2025) and 34.23% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Incyte | 25.09 Bn | 10.02 Bn | 1.57 Bn | 43.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 43.27% |
| Mar 31, 2026 | 25.53% |
| Dec 31, 2025 | 23.88% |
| Sep 30, 2025 | 34.23% |
| Jun 30, 2025 | 45.51% |
| Mar 31, 2025 | 21.61% |
| Dec 31, 2024 | 27.51% |
| Sep 30, 2024 | 14.82% |
| Jun 30, 2024 | -43.70% |
| Mar 31, 2024 | 12.92% |
| Dec 31, 2023 | 20.63% |
| Sep 30, 2023 | 25.69% |
| Jun 30, 2023 | 22.43% |
| Mar 31, 2023 | 5.44% |
| Dec 31, 2022 | 9.53% |
| Sep 30, 2022 | 18.83% |
| Jun 30, 2022 | 29.73% |
| Mar 31, 2022 | 18.14% |
| Dec 31, 2021 | 14.56% |
| Sep 30, 2021 | 30.76% |
API Access
Incyte EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=INCY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "INCY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=INCY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();